Erythropoietin fails to reverse the anemia in mice continuously exposed to tumor necrosis factor-alpha in vivo

U. Clibon, Lynda Bonewald, J. Caro, G. David Roodman

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Tumor necrosis factor-α (TNF) is a monokine produced by activated macrophages that has cytotoxic and cytostatic effects on erythroid progenitor cells. We have recently shown that Chinese hamster ovary cells transfected with the human TNF gene and which constitutively express TNF induced a hypoproliferative anemia, mild thrombocytopenia, and mild leukocytosis when injected into nude mice. We have used this murine model to determine if treatment with recombinant human erythropoietin can prevent or ameliorate the anemia seen with long-term continuous exposure to high concentrations of TNF. Mice bearing TNF-producing tumors became anemic with hematocrits ranging from 30 to 32%. Treatment with recombinant human erythropoietin (100-1000 U/kg body weight three times per week) increased the reticulocyte counts initially in mice bearing TNF-producing tumors but failed to reverse the anemia seen in these animals. Erythropoietin did not significantly increase the number of marrow erythroid colony-forming units (CFU-E) or erythroid burst-forming units (BFU-E) in mice bearing TNF-producing tumors. The data suggest that erythropoietin could not sufficiently overcome the decreased number of erythroid progenitors in mice bearing tumors producing high levels of TNF to correct their anemia.

Original languageEnglish (US)
Pages (from-to)438-441
Number of pages4
JournalExperimental Hematology
Volume18
Issue number5
StatePublished - 1990
Externally publishedYes

Fingerprint

Erythropoietin
Erythroid Precursor Cells
Anemia
Tumor Necrosis Factor-alpha
Neoplasms
Monokines
Reticulocyte Count
Leukocytosis
Cytostatic Agents
Cricetulus
Hematocrit
Nude Mice
Thrombocytopenia
Ovary
Bone Marrow
Macrophages
Body Weight
Genes

Keywords

  • Anemia
  • Erythroid progenitors
  • Erythropoietin
  • TNF

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Genetics
  • Hematology
  • Oncology
  • Transplantation

Cite this

Erythropoietin fails to reverse the anemia in mice continuously exposed to tumor necrosis factor-alpha in vivo. / Clibon, U.; Bonewald, Lynda; Caro, J.; Roodman, G. David.

In: Experimental Hematology, Vol. 18, No. 5, 1990, p. 438-441.

Research output: Contribution to journalArticle

@article{84effbd63ba5425f972a9b0a6e4757ac,
title = "Erythropoietin fails to reverse the anemia in mice continuously exposed to tumor necrosis factor-alpha in vivo",
abstract = "Tumor necrosis factor-α (TNF) is a monokine produced by activated macrophages that has cytotoxic and cytostatic effects on erythroid progenitor cells. We have recently shown that Chinese hamster ovary cells transfected with the human TNF gene and which constitutively express TNF induced a hypoproliferative anemia, mild thrombocytopenia, and mild leukocytosis when injected into nude mice. We have used this murine model to determine if treatment with recombinant human erythropoietin can prevent or ameliorate the anemia seen with long-term continuous exposure to high concentrations of TNF. Mice bearing TNF-producing tumors became anemic with hematocrits ranging from 30 to 32{\%}. Treatment with recombinant human erythropoietin (100-1000 U/kg body weight three times per week) increased the reticulocyte counts initially in mice bearing TNF-producing tumors but failed to reverse the anemia seen in these animals. Erythropoietin did not significantly increase the number of marrow erythroid colony-forming units (CFU-E) or erythroid burst-forming units (BFU-E) in mice bearing TNF-producing tumors. The data suggest that erythropoietin could not sufficiently overcome the decreased number of erythroid progenitors in mice bearing tumors producing high levels of TNF to correct their anemia.",
keywords = "Anemia, Erythroid progenitors, Erythropoietin, TNF",
author = "U. Clibon and Lynda Bonewald and J. Caro and Roodman, {G. David}",
year = "1990",
language = "English (US)",
volume = "18",
pages = "438--441",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Erythropoietin fails to reverse the anemia in mice continuously exposed to tumor necrosis factor-alpha in vivo

AU - Clibon, U.

AU - Bonewald, Lynda

AU - Caro, J.

AU - Roodman, G. David

PY - 1990

Y1 - 1990

N2 - Tumor necrosis factor-α (TNF) is a monokine produced by activated macrophages that has cytotoxic and cytostatic effects on erythroid progenitor cells. We have recently shown that Chinese hamster ovary cells transfected with the human TNF gene and which constitutively express TNF induced a hypoproliferative anemia, mild thrombocytopenia, and mild leukocytosis when injected into nude mice. We have used this murine model to determine if treatment with recombinant human erythropoietin can prevent or ameliorate the anemia seen with long-term continuous exposure to high concentrations of TNF. Mice bearing TNF-producing tumors became anemic with hematocrits ranging from 30 to 32%. Treatment with recombinant human erythropoietin (100-1000 U/kg body weight three times per week) increased the reticulocyte counts initially in mice bearing TNF-producing tumors but failed to reverse the anemia seen in these animals. Erythropoietin did not significantly increase the number of marrow erythroid colony-forming units (CFU-E) or erythroid burst-forming units (BFU-E) in mice bearing TNF-producing tumors. The data suggest that erythropoietin could not sufficiently overcome the decreased number of erythroid progenitors in mice bearing tumors producing high levels of TNF to correct their anemia.

AB - Tumor necrosis factor-α (TNF) is a monokine produced by activated macrophages that has cytotoxic and cytostatic effects on erythroid progenitor cells. We have recently shown that Chinese hamster ovary cells transfected with the human TNF gene and which constitutively express TNF induced a hypoproliferative anemia, mild thrombocytopenia, and mild leukocytosis when injected into nude mice. We have used this murine model to determine if treatment with recombinant human erythropoietin can prevent or ameliorate the anemia seen with long-term continuous exposure to high concentrations of TNF. Mice bearing TNF-producing tumors became anemic with hematocrits ranging from 30 to 32%. Treatment with recombinant human erythropoietin (100-1000 U/kg body weight three times per week) increased the reticulocyte counts initially in mice bearing TNF-producing tumors but failed to reverse the anemia seen in these animals. Erythropoietin did not significantly increase the number of marrow erythroid colony-forming units (CFU-E) or erythroid burst-forming units (BFU-E) in mice bearing TNF-producing tumors. The data suggest that erythropoietin could not sufficiently overcome the decreased number of erythroid progenitors in mice bearing tumors producing high levels of TNF to correct their anemia.

KW - Anemia

KW - Erythroid progenitors

KW - Erythropoietin

KW - TNF

UR - http://www.scopus.com/inward/record.url?scp=0025108516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025108516&partnerID=8YFLogxK

M3 - Article

C2 - 2338132

AN - SCOPUS:0025108516

VL - 18

SP - 438

EP - 441

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 5

ER -